Todd Berard Sells 424 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 424 shares of BioLife Solutions stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $25.46, for a total value of $10,795.04. Following the sale, the chief marketing officer now owns 106,538 shares in the company, valued at $2,712,457.48. This represents a 0.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Todd Berard also recently made the following trade(s):

• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total value of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $9,267.86.

BioLife Solutions Stock Up 5.7 %

BLFS stock opened at $26.25 on Thursday. BioLife Solutions, Inc. has a 1-year low of $14.84 and a 1-year high of $29.55. The business has a fifty day moving average price of $26.67 and a 200-day moving average price of $25.48. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The stock has a market capitalization of $1.22 billion, a P/E ratio of -24.76 and a beta of 1.91.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. During the same quarter in the previous year, the business earned ($0.21) earnings per share. Equities analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BLFS has been the topic of several research reports. Northland Securities lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. Benchmark reiterated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright lowered their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. TD Cowen lifted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, KeyCorp lifted their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.43.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BLFS. Raymond James Financial Inc. bought a new position in BioLife Solutions in the fourth quarter valued at about $20,664,000. Massachusetts Financial Services Co. MA bought a new position in BioLife Solutions in the fourth quarter valued at about $19,805,000. Point72 Asset Management L.P. bought a new position in BioLife Solutions in the fourth quarter valued at about $11,113,000. Millennium Management LLC increased its position in BioLife Solutions by 49.1% in the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock worth $29,733,000 after buying an additional 377,111 shares in the last quarter. Finally, Rockefeller Capital Management L.P. increased its position in BioLife Solutions by 81.3% in the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after buying an additional 262,504 shares in the last quarter. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.